(E/Z) -Necrosulfonamide

CAT: 0804-HY-100573A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-100573A-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
(E/Z) -Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573) . Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
CAS Number
[432531-71-0]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Caspase; Heme Oxygenase (HO) ; Interleukin Related; Keap1-Nrf2; Mixed Lineage Kinase; Necroptosis; NO Synthase; NOD-like Receptor (NLR) ; Pyroptosis; TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Endocrinology; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/e-z-necrosulfonamide.html
Purity
98.84
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(/C=C/C1=CC=C(S1)[N+]([O-])=O)NC2=CC=C(C=C2)S(=O)(NC3=NC=CN=C3OC)=O
Molecular Formula
C18H15N5O6S2
Molecular Weight
461.47
Precautions
H302, H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Sun L, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148 (1-2) :213-227.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-100573-01Necrosulfonamide
HY-100573RNecrosulfonamide (Standard)
HY-100573S-01Necrosulfonamide-d4
HY-123960B-01(E/Z) -Raphin1
HY-126390(E/Z) -BCI
HY-112149A-01(E/Z) -ZL0420
HY-13225E(E/Z) -Rivanicline
HY-137451A-01(E/Z) -Sivopixant
HY-145915A-01(E/Z) -ZINC09659342
HY-13779-01(E/Z) -J147

Alternative Products

CatalogName
BUP09704-01(E/Z) -Necrosulfonamide
217559MLKL Inhibitor, Necrosulfonamide ((E) -N- (4- (N- (3-Methoxypyrazin-2-yl) sulfamoyl) phenyl) -3- (5-nitrothiophene-2-yl) acrylamide, Mixed Lineage Kinase Domain-like Protein Inhibitor, Necrosome Inhibitor II, Necrosulfonamide) discontinued
TRC-N388600-1MGNecrosulfonamide

Popular Products